Trials / Completed
CompletedNCT05936268
Safety and Efficacy of Genakumab for Injection in Patients With Gout Flare
A Randomized, Open Lable, Multi-center, Active Competitor Phase 2 Study for Evaluating Efficacy and Safety of Genakumab for Injection as First Line Therapy in Patients With Gout Flare
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of Genakumab for Injection in patients with gout flare as a first line therapy
Detailed description
Phase 2， randomized, open lable, multi-center, active controlled study. Patients are randomized to Genakumab 200mg single injection group or Etoricorxib 120mg qd po.(until remission or intorlerance, no longer than 8 days) group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Genakumab for injection | 150 mg/1ml/bottle |
| DRUG | Colchicine | 0.5mg/table |
Timeline
- Start date
- 2023-07-21
- Primary completion
- 2024-02-28
- Completion
- 2024-02-28
- First posted
- 2023-07-07
- Last updated
- 2024-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05936268. Inclusion in this directory is not an endorsement.